Unicycive Therapeutics (UNCY) said late Friday it has increased the number of shares that may be sold in an "at-the-market" offering with Guggenheim Securities to $150 million.
Its previous sales agreement was to sell shares of up to $100 million from time to time through the ATM offering, according to its regulatory filing. The firm said it has filed a shelf registration statement for the offering.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments